Correction to “Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis”

doi:10.1124/jpet.123.001639err

See original article:

Pharmacology of a Potent and Novel Inhibitor of the NOD-Like Receptor Pyrin Domain-Containing Protein 3 (NLRP3) Inflammasome that Attenuates Development of Nonalcoholic Steatohepatitis and Liver Fibrosis - August 01, 2023

In the above article [Povero D, Lazic M, McBride C, Ambrus-Aikelin G, Stansfield R, Johnson CD, Santini AM, Pranadinata RF, McGeough MD, Stafford JA, Hoffman HM, Feldstein AE, Veal JM, and Bain G (2023) J Pharmacol Exp Ther 386(2):242–258; DOI: https://doi.org/10.1124/jpet.123.001639] the authors accidentally left out the financial disclosure statement which is provided below.

Financial Disclosure Statement:

AE Feldstein is currently (since July 2022) an employee and stockholder of Novo Nordisk. No other author has an actual or perceived conflict of interest with the contents of this article.

The PDF and HTML versions of the article have been corrected.

The authors apologize for any inconvenience caused by this error.